Flashcards in Hypoglycemic drugs + dopamine agonist Deck (16)
Hypoglycemic drugs (2 groups)
2nd generation sulfonylureas (3 drugs)
Sulfonylurea drugs - MOA
1) Inh ATP-sensitive potassium channels, activation of pulsatile insulin secretion. No effect on basal insulin secretion.
2) Decreasing glucagon secretion by ⇑ insulin and pancreatic somatostatin secretion.
3) Increase insulin sensitivity in DM2
Can sulfonylurea drugs be combined with metformin?
Sulfonylurea drugs - adverse effects
The effectiveness of sulfonylurea drugs is decreased by (5 drugs)
The hypoglycemic effect of sulfonylurea drugs is increased by (5 drugs)
Salicylates + other NSAIDs
What should be avoided in sulfonylurea treatment?
High alcohol consumption - disulfiram-like reaction
Meglitinide drugs (2 drugs)
Meglitinide drugs- MOA
Inh ATP-sensitive potassium channels, preventing K+-efflux and causing Ca2+-influx and activation of pulsatile insulin secretion. No effect on basal insulin secretion.
Meglitinides - indications
DM2 (1st line)
Can meglitinides be used with metformin?
Meglitinides should not be used with
Other oral antidiabetic drugs or insulin. (metformin is ok)
First-line drugs for DM2 (4 drugs/groups)
Dopamine agonist that is studied for its effect in DM